Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury. (MSC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01274975|
Recruitment Status : Completed
First Posted : January 12, 2011
Last Update Posted : March 26, 2014
|Condition or disease||Intervention/treatment||Phase|
|Spinal Cord Injury||Other: Autologous Adipose Derived Mesenchymal Stem Cells||Phase 1|
Adipose derived mesenchymal stem cells (AdMSCs) represent an attractive and ethical cell source for stem cell therapy.
With the recent demonstration of MSC homing properties, intravenous aplications of MSCs to cell-damaged diseases have increased.
In a human clinical trial, eight male patients who had suffered a spinal cord injury were intravenously administered autologous hAdMSCs (4×10e8 cells) one time.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety of Autologous Adipose Derived Mesenchymal Stem Cells in Patients With Spinal Cord Injury|
|Study Start Date :||July 2009|
|Actual Primary Completion Date :||November 2009|
|Actual Study Completion Date :||February 2010|
- Other: Autologous Adipose Derived Mesenchymal Stem Cells
Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cellsOther Name: Astrostem®
- safety evaluation [ Time Frame: 12weeks ]Safety evaluate through physical examination, vital sign and laboratory test after "RNL-Astrostem" injected
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01274975
|Principal Investigator:||SangHan Kim, MD||Anyang Sam Hospital|